GLP-1 Resource Center

What is Ozempic face and how do I prevent it?

Ozempic face is a term used to describe the facial changes that occur during rapid weight loss on GLP-1 medications. It is one of the most searched GLP-1 topics in 2026, and one that has a nutritional intervention most patients are never told about.

What causes it

The primary cause is rapid fat loss from the face. Fat gives the face structure, volume, and a youthful appearance. When weight loss occurs quickly, as it does on GLP-1 medications, facial fat depletes alongside body fat, leading to hollowed temples, flattened cheeks, deepened nasolabial folds, and more prominent bone structure. The 2026 Allergan Aesthetics survey found that 61% of GLP-1 patients experience midface volume loss, 50% experience skin laxity, and 35% experience visible wrinkles or folds.

Why protein is the most important preventive intervention

The rate of facial volume loss is directly correlated with the rate of overall weight loss and the proportion of lean mass versus fat mass lost. Patients who lose significant muscle alongside fat lose facial structure faster. Adequate protein intake slows the rate of lean mass loss, which in turn slows the rate of facial volume depletion. Research consistently shows that up to 40% of weight lost on GLP-1 medications is lean mass. Protecting that proportion protects facial structure.

The TAKE approach

TAKE Nourish provides 20g of complete plant protein per serving to help GLP-1 patients meet protein targets that directly protect lean mass and collagen synthesis during rapid weight loss. TAKE Build adds 5,000mg of creatine monohydrate to further protect lean mass. Both are included in The Strength System.

These statements have not been evaluated by the Food and Drug Administration. TAKE products are not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting any new supplement.